# Ipamorelin Research: GH-Axis Mechanism, Human PK, and the Key Studies > Ipamorelin research, in depth — the GHS-R1a mechanism, the GH-to-IGF-1 axis, the human pharmacokinetics, the failed Phase 2 trial, and the GHRP synergy data behind the cjc-1295 stack. Fully cited. Mechanism, pharmacokinetics, the human trial, and the GHRP-class synergy data — each finding led by what was measured. ## Before the details The Ipamorelin research story is unusually tidy at the front end and unusually thin at the back. Up front: a five-amino-acid peptide that flips one switch — the ghrelin receptor on the pituitary — and produces a sharp, selective burst of growth hormone, proven across rat cells, live rats, and pigs [1]. In people, a single clean study mapped how fast it comes and goes (a roughly 2-hour half-life, one GH pulse about 40 minutes after dosing) [2]. The thin part: only one human efficacy trial was ever published, and it did not hit its goal [3]. The rest of the human-relevant logic — especially for pairing ipamorelin with GHRH peptides like CJC-1295 — comes from studies of *related* peptides in the same class, which is why this page is careful to say, every time, which compound was actually tested. Below, each major finding gets its own heading. ## The mechanism: one receptor, a selective pulse Ipamorelin works by activating GHS-R1a — the growth hormone secretagogue receptor type 1a, which is the ghrelin receptor — on pituitary somatotrophs (the cells that make GH). Activation opens a Gq/PLC calcium signal inside the cell and triggers GH release [1]. The defining result is selectivity: in the founding 1998 study, ipamorelin matched GHRP-6's GH-releasing potency (swine ED50 2.3 nmol/kg) yet did not raise ACTH or cortisol above the level seen with GHRH alone, even at doses more than 200-fold above its GH ED50 [1]. That the receptor mechanism is *secretory*, not transcriptional, was sharpened in an unexpected model: in black seabream pituitary cells, ipamorelin and GHRP-2 released GH dose-dependently with nanomolar EC50 — but without changing GH gene transcription even out to 48 hours [7]. The cell was releasing stored GH, not making more of it. (Human ghrelin, oddly, did not produce dose-dependent release in that fish model — a reminder that mechanism details can shift across species.) ## The GH-to-IGF-1 axis, and why bone moved without IGF-1 moving Growth hormone's downstream partner is IGF-1, which the liver releases in response to GH. But the two don't always track over short windows. In adult female rats given subcutaneous ipamorelin at 18, 90, and 450 µg/day for 15 days, longitudinal bone growth rose dose-dependently from 42 µm/day (vehicle) to 44, 50, and 52 µm/day — with *no* measurable change in total IGF-1, IGFBPs, or bone-turnover markers [4]. The reading is that part of the skeletal effect is driven locally by the GH pulse itself rather than by a systemic IGF-1 rise. Sustained dosing tells a more IGF-1-positive story — through a class cousin. A 30-day continuous subcutaneous infusion of GHRP-2 (a GHS-R1a agonist of the same class as ipamorelin) held pulsatile GH, IGF-1, IGFBP-3, and IGFBP-5 elevated in older men and women *without tachyphylaxis* — the response did not fade [8]. Ipamorelin itself was not the infused compound; this is the class-level principle that the GH axis can stay responsive over weeks. ## Human pharmacokinetics: clean, fast, and dose-proportional The single best human dataset comes from healthy male volunteers given five 15-minute IV infusions spanning 4.21–140.45 nmol/kg. Population PK/PD modeling showed dose-proportional kinetics, a terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg; the GH response arrived as a single discrete pulse peaking at about 0.67 h — roughly 40 minutes — after dosing [2]. In rats, ipamorelin's plasma clearance is roughly 5-fold lower than GHRP-6's, with 60–80% of the dose recovered intact in bile and urine and an intranasal bioavailability around 20% [12]. The picture is a metabolically stable peptide with crisp, predictable behavior. ## Does cjc-1295 ipamorelin work? There is no controlled human trial of the cjc-1295 ipamorelin combination for any outcome, so the honest answer is that the combination's efficacy is not established — it rests on single-agent pharmacology plus class-level synergy data. What is established is the rationale: ipamorelin (a GHRP acting at GHS-R1a) and CJC-1295 (a GHRH analog acting at the GHRH receptor) hit two complementary pathways, and in related-peptide studies that pairing is genuinely synergistic [9][10]. Whether that translates to the body-composition outcomes people seek has not been tested. ## GHRP + GHRH synergy — the logic behind the stack The pharmacological case for combining a GHRP like ipamorelin with a GHRH analog like CJC-1295 rests on class-level human and animal data — always with a related peptide standing in for ipamorelin. Co-administering hexarelin (a GHRP) with GHRH-(1-29)-NH2 produced peak GH secretion significantly greater than the arithmetic sum of each alone — true synergism (P=0.001) in healthy men — though that synergy was lost when boluses were repeated 60–120 minutes apart [9]. A 34-hour continuous GHRP-6 infusion in healthy men more than doubled integrated GH versus saline and *augmented* the GH response to superimposed GHRH boluses, with the pituitary staying sensitive throughout [10]. And in lambs, low-dose GHRP-6 plus GHRH produced higher GH peak and AUC than GHRH alone, while also synergizing with a somatostatin inhibitor — evidence the GHRP acts both at the pituitary and by easing hypothalamic somatostatin tone [11]. Each of these used hexarelin, GHRP-6, or GHRP-2 — not ipamorelin — so they carry the principle, not an ipamorelin-specific number. ## Ipamorelin cjc-1295 The ipamorelin cjc-1295 pairing is the most-searched ipamorelin topic, and the cleanest way to describe it is by mechanism. Ipamorelin gives a sharp, selective GH pulse through the ghrelin receptor [1]; CJC-1295 is a long-acting GHRH analog that lifts the baseline GHRH drive through a separate receptor. Because the two pathways are complementary, related-peptide studies show GHRP-plus-GHRH combinations exceeding the additive GH response [9][10]. The combination itself, though, has no published human outcome trial — its evidence is the pharmacology of its two parts, not a study of the two together. ## The human efficacy trial — and the recent data The defining human efficacy anchor is also a cautionary one. The only published Phase 2 RCT (NCT00672074) gave 0.03 mg/kg IV twice daily for up to 7 days to 114 adults recovering from bowel resection, and it missed its primary endpoint: median time to first tolerated meal was 25.3 h with ipamorelin versus 32.6 h with placebo (p=0.15), with treatment-emergent adverse events in 87.5% of the ipamorelin arm versus 94.8% of placebo — no ipamorelin-specific safety signal in that short window, but no demonstrated efficacy either [3]. The freshest in-vivo data is a 2024 ferret study: intraperitoneal ipamorelin (1–3 mg/kg) cut cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase, though it had no anti-emetic effect [5]. And a 2026 gerontology review groups ipamorelin among non-approved peptides that lack long-term safety data and validated monitoring frameworks, explicitly contrasting it with FDA-approved agents that carry large-scale trial safety profiles [15]. The trajectory of the evidence is: elegant mechanism, expanding preclinical interest, and a human record that is still mostly a single negative trial. --- An optimistic, plain-English ordering of the ipamorelin record — the selective GH pulse logged where the studies confirm it, the cortisol and prolactin pathways left dark, the lone failed human trial kept in full view, and the community reports walled off as anecdote; a reading console pointed at the science, never a clinic, and nothing here dosed, prescribed, or sold.